Nirmatrelvir/ritonavir (Paxlovid®): French pharmacovigilance survey 2022
Description
CONCLUSION: Overall, this analysis shows that nirmatrelvir/ritonavir safety profile was conform to current summary of product characteristics (SmPC). The main concern was the risk of DDI. Therefore, SmPC and expert recommendations should be